Publicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (121)

2023

  1. C60-based Multivalent Glycoporphyrins Inhibit SARS-CoV-2 Specific Interaction with the DC-SIGN Transmembrane Receptor

    Small

  2. Clinical outcomes and antibody transfer in a cohort of infants with in utero or perinatal exposure to SARS-CoV-2 (Coronascope Study)

    European Journal of Pediatrics, Vol. 182, Núm. 10, pp. 4647-4654

  3. Corrigendum to “Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)” (EBioMedicine (2020) 55, (S2352396420301547), (10.1016/j.ebiom.2020.102779))

    eBioMedicine

  4. Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccines

    Journal of Medical Virology, Vol. 95, Núm. 1

  5. Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2

    Advanced Science, Vol. 10, Núm. 34

  6. Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2

    Viruses, Vol. 15, Núm. 7

  7. MAFB shapes human monocyte–derived macrophage response to SARS-CoV-2 and controls severe COVID-19 biomarker expression

    JCI Insight, Vol. 8, Núm. 24

  8. Multifrequency Nanomechanical Mass Spectrometer Prototype for Measuring Viral Particles Using Optomechanical Disk Resonators

    Proceedings of the IEEE International Conference on Micro Electro Mechanical Systems (MEMS)

  9. Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters

    Frontiers in Immunology, Vol. 14

  10. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates

    Frontiers in Immunology, Vol. 14

  11. Rapid screening of SARS-CoV-2 variants, a key tool for pandemic surveillance

    Scientific Reports, Vol. 13, Núm. 1

  12. Superior neutralizing response after first versus second SARS-CoV-2 infection in fully vaccinated individuals

    Journal of Medical Virology, Vol. 95, Núm. 11

  13. TLR7 Activation in M-CSF-Dependent Monocyte-Derived Human Macrophages Potentiates Inflammatory Responses and Prompts Neutrophil Recruitment

    Journal of Innate Immunity, Vol. 15, Núm. 1, pp. 517-530

  14. The role of DC-SIGN as a trans-receptor in infection by MERS-CoV

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  15. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe

    Clinical Infectious Diseases, Vol. 76, Núm. 9, pp. 1628-1635

2022

  1. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses

    Frontiers in Immunology, Vol. 13

  2. First confirmation of importation and transmission in Spain of the newly identified SARS-CoV-2 B.1.1.7 variant

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 40, Núm. 10, pp. 546-549

  3. Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice

    npj Vaccines, Vol. 7, Núm. 1

  4. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection

    Frontiers in Immunology, Vol. 13

  5. Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance

    Open Forum Infectious Diseases, Vol. 9, Núm. 11